FindTrial
Sign In

Herombopag

DRUG7 trials

Sponsors

SuxiaLuo, Institute of Hematology & Blood Diseases Hospital, China, Yin Jie, Jiangsu HengRui Medicine Co., Ltd., Peking University Cancer Hospital & Institute

Conditions

Carcinoma;BloodCervical CancerChemotherapeutic ToxicityChemotherapy-induced ThrombocytopeniaHER2-positive Breast CancerHerombopagImmune ThrombocytopeniaNon Severe Aplastic Anemia

Phase 2

Herombopag for Chemotherapy-induced Thrombocytopenia
RecruitingNCT05236582
Institute of Hematology & Blood Diseases Hospital, ChinaChemotherapy-induced Thrombocytopenia, Herombopag
Start: 2022-03-14End: 2025-12-31Target: 50Updated: 2025-02-24
Herombopag Added to Cyclosporine in Non Severe Aplastic Anemia
CompletedNCT05660785
Institute of Hematology & Blood Diseases Hospital, ChinaNon Severe Aplastic Anemia, Untreated
Start: 2022-12-01End: 2025-01-28Updated: 2025-08-05
Herombopag for the Prevention of Radio-chemotherapy Induced Thrombocytopenia in Cervical Cancer
Not yet recruitingNCT06745219
Peking University Cancer Hospital & InstituteCervical Cancer, Chemotherapeutic Toxicity, Radiotherapy Side Effect +1
Start: 2025-01-01End: 2025-07-30Target: 30Updated: 2024-12-20

Phase 3

Herombopag + rhTPO in Severe Immune Thrombocytopenia
NCT05328804
Yin JieImmune Thrombocytopenia
Start: 2022-01-01End: 2023-12-31Target: 90Updated: 2022-04-26
Extension Study of Herombopag for Pediatric Patients With Chronic Immune Thrombocytopenia
NCT05685420
Jiangsu HengRui Medicine Co., Ltd.Immune Thrombocytopenia
Start: 2023-01-23End: 2024-06-30Target: 117Updated: 2023-01-17

Unknown Phase

A Real-world Study of Herombopag in the Treatment of Thrombocytopenia Related Diseases in Henan Province
NCT05130424
SuxiaLuoCarcinoma;Blood
Start: 2021-09-29End: 2023-09-30Target: 498Updated: 2021-11-23
Primary Prevention of Thrombocytopenia Associated With T-DM1 Therapy in HER2 Positive Breast Cancer With Herombopag
Not yet recruitingNCT07198672
Zhenzhen LiuHER2-positive Breast Cancer
Start: 2025-10-31End: 2028-10-31Target: 45Updated: 2025-09-30

Related Papers

Hetrombopag Added to Cyclosporine as the First-Line Treatment for Patients With Non-Severe Aplastic Anemia: A Phase 2 Multicenter Trial.
2026-01-05